Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid
leukemia in combination with standard agents used to treat this disease.